Ionis Pharmaceuticals (NASDAQ:IONS) EVP Richard Geary Sells 1,601 Shares

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) EVP Richard Geary sold 1,601 shares of the stock in a transaction on Wednesday, November 5th. The shares were sold at an average price of $75.01, for a total transaction of $120,091.01. Following the sale, the executive vice president directly owned 59,657 shares of the company’s stock, valued at $4,474,871.57. The trade was a 2.61% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Ionis Pharmaceuticals Price Performance

IONS stock opened at $73.55 on Friday. The stock has a market capitalization of $11.91 billion, a price-to-earnings ratio of -43.52 and a beta of 0.33. The firm’s 50-day moving average price is $67.11 and its two-hundred day moving average price is $48.10. The company has a current ratio of 2.87, a quick ratio of 2.86 and a debt-to-equity ratio of 0.99. Ionis Pharmaceuticals, Inc. has a 12-month low of $23.95 and a 12-month high of $76.78.

Ionis Pharmaceuticals (NASDAQ:IONS) last posted its earnings results on Wednesday, October 29th. The company reported ($0.80) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.15) by $0.35. Ionis Pharmaceuticals had a negative return on equity of 45.29% and a negative net margin of 26.45%.The company had revenue of $157.00 million for the quarter, compared to analysts’ expectations of $131.75 million. During the same period last year, the firm earned ($0.95) earnings per share. Ionis Pharmaceuticals’s quarterly revenue was up 17.2% on a year-over-year basis. Ionis Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, equities analysts predict that Ionis Pharmaceuticals, Inc. will post -3.5 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. Citigroup boosted their target price on Ionis Pharmaceuticals from $69.00 to $84.00 and gave the company a “buy” rating in a research note on Wednesday, September 3rd. Oppenheimer boosted their price objective on shares of Ionis Pharmaceuticals from $84.00 to $90.00 and gave the company an “outperform” rating in a research report on Wednesday, October 8th. HC Wainwright raised their target price on shares of Ionis Pharmaceuticals from $95.00 to $100.00 and gave the stock a “buy” rating in a research report on Thursday, October 30th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Ionis Pharmaceuticals in a research note on Wednesday, October 8th. Finally, Royal Bank Of Canada increased their price target on shares of Ionis Pharmaceuticals from $80.00 to $82.00 and gave the stock an “outperform” rating in a research note on Thursday, October 30th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $83.65.

Institutional Investors Weigh In On Ionis Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in IONS. Adage Capital Partners GP L.L.C. increased its holdings in shares of Ionis Pharmaceuticals by 253.3% during the second quarter. Adage Capital Partners GP L.L.C. now owns 3,800,000 shares of the company’s stock valued at $150,138,000 after acquiring an additional 2,724,400 shares in the last quarter. T. Rowe Price Investment Management Inc. boosted its stake in Ionis Pharmaceuticals by 14.2% in the 1st quarter. T. Rowe Price Investment Management Inc. now owns 16,175,533 shares of the company’s stock worth $488,016,000 after purchasing an additional 2,006,334 shares in the last quarter. BVF Inc. IL purchased a new stake in Ionis Pharmaceuticals during the 1st quarter valued at about $57,727,000. Vestal Point Capital LP bought a new stake in Ionis Pharmaceuticals during the 2nd quarter valued at about $19,755,000. Finally, Norges Bank bought a new stake in Ionis Pharmaceuticals during the 2nd quarter valued at about $17,790,000. 93.86% of the stock is owned by institutional investors.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.